About Organogenesis
Organogenesis is a company based in Canton (United States) founded in 1985 was acquired by Avista Capital Partners in August 2018.. Organogenesis has raised $30 million across 4 funding rounds from investors including Eastward Capital Partners, Massachusetts Life Sciences Center and Avista Capital Partners. The company has 869 employees as of December 31, 2024. Organogenesis has completed 1 acquisition, including Nutech Medical. Organogenesis offers products and services including PuraPlyAM, NuShield, Apligraf, and Affinity. Organogenesis operates in a competitive market with competitors including Tenaya Therapeutics, Athira Pharma, Ensoma, Orca Bio and Avita Medical, among others.
- Headquarter Canton, United States
- Employees 869 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Organogenesis Holdings Inc.
-
Annual Revenue
$482.04 M11.29as on Dec 31, 2024
-
Net Profit
$861 K-82.59as on Dec 31, 2024
-
EBITDA
$47.11 M18.45as on Dec 31, 2024
-
Total Equity Funding
$30 M (USD)
in 4 rounds
-
Latest Funding Round
$130 M (USD), Post-IPO
Nov 12, 2024
-
Investors
Eastward Capital Partners
& 2 more
-
Employee Count
869
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
Avista Capital Partners
(Aug 17, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Organogenesis
Organogenesis is a publicly listed company on the NASDAQ with ticker symbol ORGO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Organogenesis
Organogenesis offers a comprehensive portfolio of products and services, including PuraPlyAM, NuShield, Apligraf, and Affinity. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Regenerative matrix for advanced wound healing treatments.
Biological graft for tissue repair in medical procedures.
Engineered skin substitute for chronic wound management.
Matrix for surgical and sports medicine applications.
Unlock access to complete
Sales and Marketing
51 people
Software Development Team
26 people
Leadership Team
22 people
Product Management Team
13 people
Senior Team
7 people
QC Team
6 people
Operations Team
6 people
Customer Team
6 people
Unlock access to complete
Funding Insights of Organogenesis
Organogenesis has successfully raised a total of $30M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $130 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $130.0M
-
First Round
First Round
(27 Jan 2009)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Post-IPO - Organogenesis | Valuation |
investors |
|
| May, 2017 | Amount | Debt – Conventional - Organogenesis | Valuation |
investors |
|
| Apr, 2016 | Amount | Series C - Organogenesis | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Organogenesis
Organogenesis has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Eastward Capital Partners, Massachusetts Life Sciences Center and Avista Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm that does debt investment in the US
|
Founded Year | Domain | Location | |
|
Life sciences innovation is supported through funding and programs.
|
Founded Year | Domain | Location | |
|
Private equity investments are focused on the United States market.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Organogenesis
Organogenesis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nutech Medical. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Biologic and medical device company focusing on spinal and orthopedic surgical products
|
1994 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Organogenesis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Organogenesis Comparisons
Competitors of Organogenesis
Organogenesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Athira Pharma, Ensoma, Orca Bio and Avita Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed.
|
|
| domain | founded_year | HQ Location |
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool
|
|
| domain | founded_year | HQ Location |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| domain | founded_year | HQ Location |
Products for regenerative and respiratory medicine are developed and distributed.
|
|
| domain | founded_year | HQ Location |
Cell and gene therapies are developed via an epigenomic platform.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Organogenesis
Frequently Asked Questions about Organogenesis
When was Organogenesis founded?
Organogenesis was founded in 1985 and raised its 1st funding round 24 years after it was founded.
Where is Organogenesis located?
Organogenesis is headquartered in Canton, United States. It is registered at Canton, Ohio, United States.
Who is the current CEO of Organogenesis?
Gary S Gillheeney is the current CEO of Organogenesis.
Is Organogenesis a funded company?
Organogenesis is a funded company, having raised a total of $30M across 4 funding rounds to date. The company's 1st funding round was a Series C of $30M, raised on Jan 27, 2009.
How many employees does Organogenesis have?
As of Dec 31, 2024, the latest employee count at Organogenesis is 869.
What is the annual revenue of Organogenesis?
Annual revenue of Organogenesis is $482.04M as on Dec 31, 2024.
What does Organogenesis do?
Organogenesis, an MIT spin-off, develops regenerative therapies for wound care. It has four approved products on the market. Apligraf is a living cell-based human skin substitute that is indicated for the treatment of venous leg ulcers and diabetic foot ulcers. Dermagraft is a human fibroblast-derived dermal substitute for diabetic foot ulcers.PuraPly is a collagen plus polyhexanide antimicrobial wound filling matrix. Additionally, Organogenesis also received FDA clearance for Gintuit, a scaffold product made of allogeneic cultured keratinocytes and fibroblasts, indicated for mucogingival conditions in adults.
Who are the top competitors of Organogenesis?
Organogenesis's top competitors include Tenaya Therapeutics, Athira Pharma and Orca Bio.
What products or services does Organogenesis offer?
Organogenesis offers PuraPlyAM, NuShield, Apligraf, and Affinity.
Is Organogenesis publicly traded?
Yes, Organogenesis is publicly traded on NASDAQ under the ticker symbol ORGO.
How many acquisitions has Organogenesis made?
Organogenesis has made 1 acquisition, including Nutech Medical.
Who are Organogenesis's investors?
Organogenesis has 3 investors. Key investors include Eastward Capital Partners, Massachusetts Life Sciences Center, and Avista Capital Partners.
What is Organogenesis's ticker symbol?
The ticker symbol of Organogenesis is ORGO on NASDAQ.